Men and women aged 18 years or older with moderate to severe hidradenitis suppurativa (HS) for at least 1 year, may qualify to participate in this study. Individuals must have lesions present in at least 2 distinct anatomical areas. Stable HS for at least 1 month prior to the screening visit, will be determined by the study doctor.
Eligible participants will receive investigational medication (active drug) and/or placebo via injection. Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided.
Study participation will last up to 52 weeks and include about 15 visits to the study centre.
Email Tina Craig, Clincal Research Coordinator at DermEffects to register.